RATIONALE: Mesolimbic dopamine (DA), particularly in the nucleus accumbens, importantly regulates activational aspects of maternal responsiveness. DA antagonism and accumbens DA depletions interfere with early postpartum maternal motivation by selectively affecting most forms of active maternal behaviors, while leaving nursing behavior relatively intact. Considerable evidence indicates that there is a functional interaction between DA D2 and adenosine A(2A) receptors in striatal areas, including the nucleus accumbens. OBJECTIVE: This study was conducted to determine if adenosine A(2A) receptor antagonism could reverse the effects of DA receptor antagonism on early postpartum maternal behavior. METHODS: The adenosine A(2A) receptor antagonist MSX-3 (0.25-2.0 mg/kg, IP) was investigated for its ability to reverse the effects of the DA D2 receptor antagonist haloperidol (0.1 mg/kg, IP) on the maternal behavior of early postpartum female rats. RESULTS: Haloperidol severely impaired the expression of active maternal components, including retrieval and grouping the pups at the nest site, pup licking, and nest building. Co-administration of MSX-3 (0.25-2.0 mg/kg, IP) with haloperidol produced a dose-related attenuation of the haloperidol-induced behavioral deficits in early postpartum females. Doses of MSX-3 that effectively reversed the effects of haloperidol (0.5, 1.0 mg/kg), when administered in the absence of haloperidol, did not affect maternal responding or locomotor activity. CONCLUSIONS: Adenosine and DA systems interact to regulate early postpartum maternal responsiveness. This research may potentially contribute to the development of strategies for treatments of psychiatric disorders during the postpartum period, with particular emphasis in maintaining or restoring the mother-infant relationship.
RATIONALE: Mesolimbic dopamine (DA), particularly in the nucleus accumbens, importantly regulates activational aspects of maternal responsiveness. DA antagonism and accumbens DA depletions interfere with early postpartum maternal motivation by selectively affecting most forms of active maternal behaviors, while leaving nursing behavior relatively intact. Considerable evidence indicates that there is a functional interaction between DA D2 and adenosine A(2A) receptors in striatal areas, including the nucleus accumbens. OBJECTIVE: This study was conducted to determine if adenosine A(2A) receptor antagonism could reverse the effects of DA receptor antagonism on early postpartum maternal behavior. METHODS: The adenosine A(2A) receptor antagonist MSX-3 (0.25-2.0 mg/kg, IP) was investigated for its ability to reverse the effects of the DA D2 receptor antagonist haloperidol (0.1 mg/kg, IP) on the maternal behavior of early postpartum female rats. RESULTS:Haloperidol severely impaired the expression of active maternal components, including retrieval and grouping the pups at the nest site, pup licking, and nest building. Co-administration of MSX-3 (0.25-2.0 mg/kg, IP) with haloperidol produced a dose-related attenuation of the haloperidol-induced behavioral deficits in early postpartum females. Doses of MSX-3 that effectively reversed the effects of haloperidol (0.5, 1.0 mg/kg), when administered in the absence of haloperidol, did not affect maternal responding or locomotor activity. CONCLUSIONS:Adenosine and DA systems interact to regulate early postpartum maternal responsiveness. This research may potentially contribute to the development of strategies for treatments of psychiatric disorders during the postpartum period, with particular emphasis in maintaining or restoring the mother-infant relationship.
Authors: K Fuxe; L F Agnati; K Jacobsen; J Hillion; M Canals; M Torvinen; B Tinner-Staines; W Staines; D Rosin; A Terasmaa; P Popoli; G Leo; V Vergoni; C Lluis; F Ciruela; R Franco; S Ferré Journal: Neurology Date: 2003-12-09 Impact factor: 9.910
Authors: Keita Ishiwari; Lisa J Madson; Andrew M Farrar; Susana M Mingote; John P Valenta; Michael D DiGianvittorio; Lauren E Frank; Merce Correa; Jörg Hockemeyer; Christa Müller; John D Salamone Journal: Behav Brain Res Date: 2006-12-21 Impact factor: 3.332
Authors: Allison M Mott; Eric J Nunes; Lyndsey E Collins; Russell G Port; Kelly S Sink; Jörg Hockemeyer; Christa E Müller; John D Salamone Journal: Psychopharmacology (Berl) Date: 2009-01-09 Impact factor: 4.530
Authors: Matthew A Gannon; Clifford J Brown; Rachel M Stevens; Molly S Griffith; Cecile A Marczinski; Mark E Bardgett Journal: Pharmacol Biochem Behav Date: 2015-01-17 Impact factor: 3.533
Authors: P Trifilieff; B Feng; E Urizar; V Winiger; R D Ward; K M Taylor; D Martinez; H Moore; P D Balsam; E H Simpson; J A Javitch Journal: Mol Psychiatry Date: 2013-05-28 Impact factor: 15.992
Authors: Mercè Correa; Marta Pardo; Pilar Bayarri; Laura López-Cruz; Noemí San Miguel; Olga Valverde; Catherine Ledent; John D Salamone Journal: Psychopharmacology (Berl) Date: 2015-11-10 Impact factor: 4.530
Authors: Zachary A Grieb; Erika M Vitale; Joan I Morrell; Joseph S Lonstein; Mariana Pereira Journal: Psychopharmacology (Berl) Date: 2020-01-11 Impact factor: 4.530
Authors: Patrick A Randall; Christie A Lee; Eric J Nunes; Samantha E Yohn; Victoria Nowak; Bilal Khan; Priya Shah; Saagar Pandit; V Kiran Vemuri; Alex Makriyannis; Younis Baqi; Christa E Müller; Merce Correa; John D Salamone Journal: PLoS One Date: 2014-06-17 Impact factor: 3.240